Evidence map›Paper›PMID 40135926›Full record

ArticleAntimicrobial agents and chemotherapy2025

Repurposing drugs to advance the treatment of Buruli ulcer.

Sanjay Singh, Rie Yotsu, Eric Nuremberger, Shashikant Srivastava

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Buruli ulcer.Nature reviews. Disease primers · 2025
    Review
  2. New drugs for the management of tuberculosis.Current opinion in infectious diseases · 2025
    Review
  3. Life (Basel, Switzerland) · 2025
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Sanjay SinghDivision of Infectious Diseases, Department of Medicine, School of Medicine, University of Texas Health Science Centre at Tyler, Tyler, Texas, USA.ORCID 0000-0003-4601-5673
Rie YotsuDepartment of Tropical Medicine and Infectious Disease, School of Public Health and Tropical Medicine, Tulane University, New Orleans, Louisiana, USA.
Eric NurembergerCenter for Tuberculosis Research, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0003-1440-9889
Shashikant SrivastavaDivision of Infectious Diseases, Department of Medicine, School of Medicine, University of Texas Health Science Centre at Tyler, Tyler, Texas, USA.ORCID 0000-0002-8786-8851

Funding

Short course combination regimens for treatment of Mycobacterium avium pulmonary disease: a translational bench-to-bedside approachR01AI179827 · NIAID · UNIVERSITY OF TEXAS HLTH CTR AT TYLER · PI Shashi Kant · 2024 to 2026
$1.7M
HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) 1R01AI179827NIAID NIH HHS R01 AI179827
6 · The paper itself

Abstract

Aligned with the World Health Organization's Road Map, there is an unmet need for research to improve the treatment of Buruli ulcer caused by

Indexed as

Anti-Bacterial AgentsBuruli UlcerDrug RepositioningMycobacterium ulceransAnimalsClarithromycinDiarylquinolinesHumansMicrobial Sensitivity TestsMoxifloxacinRifampinTetracyclinesAnti-Bacterial AgentsbedaquilineClarithromycinDiarylquinolinesMoxifloxacinomadacyclineRifampinTetracyclinesautoluminescenceBuruli ulcerdrug susceptibilityMycobacterium ulceransrepurposing

Identifiers

PMID40135926
PMCPMC12057354

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.